GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Stock Based Compensation

NovMetaPharma Co (XKRX:229500) Stock Based Compensation : ₩451.31 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Stock Based Compensation?

NovMetaPharma Co's Stock Based Compensation for the six months ended in Dec. 2024 was ₩451.31 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was ₩451.31 Mil.


NovMetaPharma Co Stock Based Compensation Historical Data

The historical data trend for NovMetaPharma Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Stock Based Compensation Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,410.95 2,583.87 2,433.36 2,047.11 451.31

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,410.95 2,583.87 2,433.36 2,047.11 451.31

NovMetaPharma Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was ₩451.31 Mil.


NovMetaPharma Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


NovMetaPharma Co Business Description

Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines